Gout drug could cut length of hospitalisation in patients with moderate to severe COVID-19

A trial investigating the gout drug colchicine as a treatment for COVID-19 has suggested it reduces the length of both supplemental oxygen therapy and hospitalisation in patients with moderate to severe COVID-19.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research